Mutations in the DAX1 locus cause X-linked adrenal hypoplasia congenita (AHC) and hypogonadotropic hypogonadism (HH), which manifest with primary adrenal insufficiency and incomplete or absent sexual maturation, respectively. The associated defects in spermatogenesis can range from spermatogenic arrest to Sertoli cell only syndrome. Conclusions from Dax1 knockout mouse models provide only limited insight into AHC/HH disease mechanisms, because mouse models exhibit more extensive abnormalities in testicular development, including disorganized and incompletely formed testis cords with decreased number of peritubular myoid cells and male-to-female sex reversal. We previously reported successful clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9)-mediated genome targeting in cynomolgus monkeys. Here, we describe a male fetal monkey in which targeted genome editing using CRISPR/Cas9 produced Dax1-null mutations in most somatic tissues and in the gonads. This DAX1-deficient monkey displayed defects in adrenal gland development and abnormal testis architecture with small cords, expanded blood vessels and extensive fibrosis. Sertoli cell formation was not affected. This phenotype strongly resembles findings in human patients with AHC-HH caused by mutations in DAX1. We further detected upregulation of Wnt/β-catenin-VEGF signaling in the fetal Dax1-deficient testis, suggesting abnormal activation of signaling pathways in the absence of DAX1 as one mechanism of AHC-HH. Our study reveals novel insight into the role of DAX1 in HH and provides proof-of-principle for the generation of monkey models of human disease via CRISPR/Cas9-mediated gene targeting. † These authors contributed equally to this work.
Introduction
The laboratory mouse provides a powerful model for characterizing the functional consequences of genetic changes because of the feasibility of genetic manipulation of its genome (1), however, mouse models do not always fully parallel the human phenotypes (2) . Monkeys share close genetic and physiological similarities to humans (3) , but the development of monkey models of human genetic diseases has been hampered by the lack of effective approaches for genome engineering. Among several genome modification approaches that utilize reprogrammable endonucleases, the type II prokaryotic clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) adaptive immune system has emerged as a highly effective tool for the precise modification of genomic sequences in various organisms (4) . Adapted versions of this system use chimeric single-guide RNA (sgRNA) that contain a short stretch of homology with the genomic target sequence. Base pairing of the sgRNA targets the CAS9 nuclease to the desired genomic sequence, where the RNA-CAS9 complex induces DNA double-strand breaks. These are repaired either by non-homologous end-joining resulting in indels, or by homologous recombination if a corresponding donor template is present. This approach is not only highly specific but also efficient and suitable for multiplex genome engineering (4) . We successfully used CRISPR/Cas9 genome engineering in cynomolgus monkeys (Macaca fascicularis). By co-injection of Cas9 mRNA and multiple sgRNAs targeting Nr0b1 (nuclear receptor subfamily 0 group b member 1), Ppar-γ (peroxisome proliferator-activated receptor-γ) and Rag1 (recombination activating gene 1) into one-cell embryos, we have generated two live monkey founders with Ppar-γ and Rag1 mutations (5) . Targeted modifications in Ppar-γ and Rag1 were also detected in various tissues of monkey embryos that were miscarried after embryo transfer (6) . Nevertheless, whether these first knockout monkeys faithfully model human disorders resulting from target gene deficiency remain to be determined. Surprisingly, modification of the third target gene, Nr0b1, was not detected in live founders. Nr0b1, also known as Dax1 (dosagesensitive sex reversal, adrenal hypoplasia critical region, on chromosome X, gene 1), encodes an orphan nuclear receptor with functional relevance in the hypothalamic-pituitary-adrenal-gonadal axis (7, 8) . Humans with DAX1 mutations develop an X-linked inherited syndrome referred to as adrenal hypoplasia congenita (AHC). Patients typically present in infancy with adrenal insufficiency and later fail to undergo puberty because of hypogonadotropic hypogonadism (HH) associated with azoospermia (7) . Clinical signs in infancy include failure to thrive, convulsions, hyperpigmentation, vomiting, poor feeding and sudden death in the first several months of life (8) . Here, we describe the consequences of Dax1-deficiency in the monkey after CRISPR/Cas9 genome engineering in cynomolgus monkeys (5, 6) . We found targeted deletion of Dax1 in several aborted monkey fetuses, including one animal in which Dax1 was ablated in almost all tissues examined. This fetus exhibited abnormalities in testicular and adrenal gland development that strongly resembled phenotypic findings in human AHC-HH, providing a proof-ofprinciple that gene targeting in the monkey can produce models that recapitulate human genetic diseases.
Results

Dax1 targeting in the monkey via Cas9/sgRNAs
After microinjection of Cas9 mRNA and sgRNAs targeting Nr0b1, Ppar-γ and Rag1 into one-cell embryos, successful pregnancies were established in eight surrogate cynomolgus monkeys (Macaca fascicularis), from which live offspring with targeted mutations in Ppar-γ and Rag1 were obtained (5) . Four recipients with multiple pregnancies underwent miscarriage at different stages of gestation (6) ; from these, we collected eight aborted fetuses (fetuses C, D, E, F, G, K, L and M). One female infant from a single pregnancy died after birth (fetus H). Both live offspring and aborted fetuses had targeted mutations in Ppar-γ and Rag1 (5,6); however, changes in Nr0b1 (Dax1) were not detected in live founders (5) . Here, we evaluated targeted mutagenesis at the Dax1 locus in aborted fetuses, focusing on two male fetuses that had been aborted on Day 95 of gestation (male fetuses C and D). By polymerase chain reaction (PCR) amplification, T7 Endonuclease I (T7EN1) cleavage assay, and sequencing, we screened for genetic alterations at the sites targeted by Nr0b1-sgRNA1 and Nr0b1-sgRNA2 in 10 somatic tissues including heart, liver, spleen, kidney, brain, small intestine, skeletal muscle, placenta, tail and finger. Amplification of genomic target sites by PCR did not reveal detectable modifications (Fig. 1A) , however, analysis of the Nr0b1-sgRNA1 target site by T7EN1 cleavage assay revealed that this locus was modified in all evaluated tissues from fetus D (Fig. 1B) . Sequencing result confirmed the presence of an 8-bp nonsense deletion (Fig. 1C) , which was present in all samples from heart, kidney, brain, small intestine, muscle, tail and finger (100%), and detected at high frequency in liver (97%; 30 out of 31) and spleen (90%; 9 out of 10), demonstrating successful and extensive Dax1 targeting in Fetus D (Table 1) . A minor contribution of genetically modified cells (1 out of 23) was detected in placenta, which is a fetomaternal organ with both fetal and maternal components.
Potential modifications at the Dax1 locus were further evaluated in tissues from other aborted fetuses (E to H, and K to M). Targeted mutagenesis at Dax1-sg1 was confirmed in Fetus E and in multiple tissues of fetuses G and K (Supplementary Material, Fig. S1 and Table S1 ). In summary, we observed that co-injection of Cas9 and sgRNAs into one-cell embryos resulted in extensive genetic modification of Dax1 in multiple tissues of monkey embryos.
DAX1-deficiency in testis after Cas9/sgRNAs targeting
We previously reported that Cas9/sgRNAs-induced modifications in the Ppar-γ and Rag1 genes were present in the testes of fetuses and in individual germ cells isolated from the ovaries of fetal stage monkeys, including fetuses C and D, indicating contribution of genetically modified cells to the germline (6) . Here, we determined the presence and extent of targeted Dax1 mutations in the gonads of the two male aborted fetuses C and D. Testis tissue from fetus D was largely composed of cells with Nr0b1-sg-1 targeted mutations, whereas no mutations were detected in testis tissue from fetus C. Similar to findings in somatic tissues, modifications were not detectable by PCR, but apparent from the presence of multiple T7EN1 cleavage bands (Fig. 1D) . Sequencing confirmed that testis from fetus D contained the same 8-bp nonsense deletion of Nr0b1 that had been identified in somatic tissues, with a frequency of 88.89% (16 of 18; Fig. 1E ). To determine the consequences of this deletion on DAX1 protein expression in the testes, we performed western blot analysis with an antibody directed against the C-terminus of DAX1; this analysis confirmed lack of DAX1 in testis tissue from fetus D but not fetus C (Fig. 1F) . In summary, we found that Cas9/sgRNAs induced modifications in Ppar-γ and Rag1 in testis tissue from fetus C (6), and in Ppar-γ (6) and Dax1 in testis tissue from fetus D.
Dax1-deficiency causes testis dysgenesis in the monkey
Histological findings in testicular biopsies from adult patients with AHC and HH caused by DAX1 mutations have shown various defects including arrest of spermatogenesis and Sertoli cell only syndrome (7, (9) (10) (11) (12) . Oligospermia or azoospermia in human patients is unresponsive to gonadotropin therapy, suggesting primary defects in the gonads, such as germ or Sertoli cell dysfunction (8) . Male mice with a targeted deletion of Dax1 exhibit abnormal testicular development, with testis cord disorganization and dilation of seminiferous tubules resulting from obstruction with Sertoli cells and hyperplastic Leydig cells (13) . These findings suggest that DAX1 plays a critical role during fetal development of the testis. To assess the phenotypic consequences of Dax1-deficiency on prenatal testis development in the monkey, we examined testicular tissue from fetus D, which lacked detectable DAX1 protein. Gross histologic examination revealed that testis cords were present ( Fig. 2A and B ), in contrast with findings in the mouse model. However, the testis cords in fetus D were of much smaller diameter than those of controls, which included a wild-type fetus and fetus C, in which the Dax1 had remained unchanged. Furthermore, testis tissue from fetus D contained many expanded blood vessels, indicating disordered neovascularization. These findings suggested defects in testicular architecture, affecting testis cord morphology.
To further characterize the composition of the Dax1-deficient testes from fetus D, we visualized germ cells and Sertoli cells, respectively, by immunohistochemical staining with germ cell maker, DDX4 (14) and Sertoli cell marker, GATA4 (15) . Testis tissue from fetus D contained substantially fewer germ cells compared with controls but similar numbers of Sertoli cells ( Fig. 2C and D). Collagen-specific Masson staining revealed a marked increase in collagen fiber density in the DAX1-deficient testis tissue ( Fig. 2E and F) , suggesting that lack of DAX1 induces testis fibrosis formation in fetal testis. Interestingly, similar to observations in mice with a targeted deletion of Dax1 (16), Dax1-deficiency did not cause any apparent defects in other tissues including heart, liver, spleen, kidney, brain, small intestine, muscle, placenta, tail and finger (Supplementary Material, Fig. S2 ). Western blot analysis confirmed the presence of DAX1 protein in testis, adrenal gland, ovary and placenta; DAX1 was not detected in other somatic tissues including heart, liver, spleen, lung, kidney, skeletal muscle, small intestine, brain and uterus (Supplementary Material, Fig. S3 ). These findings suggest a largely testisrestricted function of Dax1 in the monkey.
Dax1-deficiency does not affect Sertoli cell identity in the monkey model
Although sex reversal has not been observed in patients with Dax1 mutations (17, 18) , studies in the mouse have demonstrated that in certain strain backgrounds, Dax1-deficiency can result in gonadal sex reversal. In these mice, pre-Sertoli cells do not upregulate SOX9 and consequently do not differentiate into Sertoli cells, leading to failure of testicular development (19) . These findings in the mouse suggest an early, essential role for Dax 1 in fetal testis development that includes the determination of Sertoli cell identity. We evaluated the expression of key Sertoli cell markers in the testes of Dax1-deficient fetal monkeys. Although Dax1-deficient testicular tissue exhibited marked alterations in architecture and contained fewer germ cells overall compared with controls ( Fig. 2A and C) , we did not detect measurable differences in the distribution of the Sertoli cell marker GATA4 compared with controls ( Fig. 2D ): GATA4 expression was restricted to the nuclei of cells identified as Sertoli cells based morphology and location. The expression level of GATA4 was comparable to controls, suggesting that Sertoli cells were formed in the testis of the Dax1-deficient fetus D.
Sertoli cell identity was further evaluated by co-immunostaining of GATA4 and other Sertoli cell markers, including AMH (anti-Mullerian hormone) (20) , Sox9 (21) and WT1 (Wilms tumor 1 homolog) (22) . Expression and intracellular distribution of AMH (Fig. 3A), SOX9 (Fig. 3B) and WT1 (Fig. 3C) in Dax1-deficient fetal monkey testis were comparable to control tissue. These results were further confirmed by immunochemical staining of AMH, Sox9 and WT1 (Fig. 3D) . We conclude that there was no evidence for any disturbances to Sertoli cell identity in the Dax1-deficient testis of monkey fetus D. Consistently, we also did not detect male-to-female sex reversal by immunostaining of Foxl2, a female-specific transcription factor expressed in granulosa cells (23) (Supplementary Material, Fig. S4 ).
Upregulation of Wnt/β-catenin signaling in Dax1-deficient testis Due to the inaccessibility of human samples, the mechanisms of the Dax1-deficiency-induced diseases remain elusive. Based on our observations that Dax1-deficiency resulted in neovascularization failure in the testis of fetus D, we evaluated potential changes in the expression of components of the Wnt/β-catenin pathway. Wnt/β-catenin signaling has been implicated in many aspects of angiogenesis, vascular remodeling and development in different tissues and species (24, 25) . Immunochemical analysis revealed increased expression of β-catenin in interstitial cells of testis tissue from fetus D compared with control ( Fig. 4A  and B) , suggesting activation of the Wnt/β-catenin pathway. Activation of the Wnt/β-catenin pathway leads to β-catenin accumulation in the cytoplasm and translocation into the nucleus, where it binds to the N terminus of LEF/TCF (lymphoid enhancer factor/T cell factor) transcription factors, acting as a co-activator in the regulation of downstream target genes including Myc, Cyclin D1 and vascular endothelial growth factor (Vegf) (26) (27) (28) . Of these, VEGF has been identified as an important factor contributing to testis neovascularization (29) . Double indirect immunofluorescence revealed that the β-catenin positive interstitial cells of testis tissue from fetus D also contained markedly elevated levels of VEGF (Fig. 4C) . This observation was further confirmed by western blot analysis demonstrating activation of the Wnt/β-catenin pathway and upregulation of VEGF in Dax1-deficient samples (Fig. 4D and E) . These results suggest that activation of Wnt/β-catenin signaling could be associated with Dax1-deficiency-induced testes dysgenesis.
Dax1-deficient adrenal gland shows abnormal morphology
Humans with Dax1 mutations display adrenal insufficiency due to impaired development of the adult zone of the adrenal cortex (8) . Similarly, mice with targeted deletion of Dax1 exhibit abnormal adrenal gland development (16) . DAX1 is expressed in the adrenal gland of the monkey (Supplementary Material, Fig. S3) . We analyzed the architecture of the adrenal glands of the Dax1-deficient fetus D at 95 days of gestation and detected enlargement of the fetal zone of the adrenal cortex compared with control tissue (Fig. 5A and B) .
Further characterization by immunohistochemical staining for P450 side-chain cleavage enzyme (P450SCC), a marker associated with steroidogenesis in the adrenal gland (30), showed reduced levels of this enzyme indicated by weaker immunohistochemical staining of P450SCC in Dax1-deficient compared with control tissue (Fig. 5C) , consistent with observations in Dax1-null mutant mice (16) . Cell proliferation as assessed by proliferating cell nuclear antigen staining was not affected (Supplementary Material, Fig. S5 ), but we detected marked cell apoptosis in the cortex of the Dax1-deficient adrenal gland (Fig. 5D ). These observations are consistent with abnormal architecture of the adrenal cortex.
To exclude any off-target activity of Cas9/sgRNA, we screened predicted off-target sites of Nr0b1-sgRNA1 and Nr0b1-sgRNA2 for the presence of modifications by T7EN1 cleavage assay (Supplementary Material, Table S2 and Fig. S6 ). PCR products yielded cleavage bands from four off-target sites were TA cloned and precisely examined by Sanger sequencing (Supplementary Material, Table S4 ). Notably, all the cleavage were caused by single-nucleotide polymorphisms (SNPs), rather than off-target mutagenesis, further supporting the Dax1-specific phenotype.
Discussion
Co-injection of Cas9 mRNA and sgRNAs into one-cell stage embryos has emerged as a versatile strategy for gene targeting in various species (31) . We successfully used this approach in cynomolgus monkeys, obtaining live offspring with Ppar-γ and Rag1 mutations after simultaneous injection of multiple sgRNAs targeting Nr0b1, Ppar-γ and Rag1 (5). Intriguingly, mutations at the Nr0b1 (Dax1) locus were not found in live offspring although cell line experiments had demonstrated effective targeting with two Nr0b1-directed sgRNAs. Here, we report that several fetuses that did not reach term after embryo transfer had extensive modifications at the Dax1 locus. These include one male fetus in which targeted mutations of Dax1 were present in most somatic tissues and the gonad, resulting in testis degeneration and aberrant development of the adrenal cortex. In contrast to findings in mouse models of DAX1-deficiency, Sertoli cell fate was not affected by the absence of DAX1 in the testis. Based on several phenotypic characteristics, we conclude that this monkey represents a more faithful model of human AHC and HH than mouse models and provides proof-of-principle for a monkey model of a human disease obtained by targeted genome engineering using CRISPR/Cas9.
Humans with DAX1 mutations develop AHC with adrenal insufficiency because of impaired development of the adult zone of the adrenal cortex (8) and fail to undergo puberty because of HH with arrested spermatogenesis or Sertoli cell only syndrome (7, (9) (10) (11) (12) . In contrast, Dax1 knockout mouse models exhibit disorganized and incompletely formed testis cords (13), male-tofemale sex reversal associated with dysregulation of several testis differentiation associated genes, including Amh, Sox9 and Wt1 (19, 32) , and impaired gonadal differentiation with development of testislike, ovarianlike or intersex gonads (33) . Testicular biopsies from AHC/HH patients with DAX1 mutations have revealed defects that include arrested spermatogenesis and Sertoli cell only syndrome, indicating that DAX1 has an essential function during fetal development of the testis. Here, we demonstrate that in the monkey, Dax1-deficiency results in a testis phenotype that resembles that of human patients and differs from that of Dax1 knockout mouse models in several aspects. First, the internal genitalia of the Dax1-deficient monkey were of grossly normal appearance, but changes in testis morphology were apparent. Moreover, AMH, SOX9 and WT1 expression were not altered. This demonstrates that Dax1 is not required for monkey sex determination. Second, in the Dax1-deficient monkey testis, the testis cords were well organized and the tubular structure remained intact with a reduced number of germ cells. Third, abnormal angiogenesis manifesting with expanded blood vessels was observed in the Dax1-deficient monkey testis; this phenotype has not been reported in the mouse model. Taken together, our data reveal that Dax1 plays a different role in the monkey and mouse reproductive system; furthermore, spermatogenesis arrested/ Sertoli cell only syndrome in human HH with Dax1 mutations is a result of aberrant fetal testis development.
The majority of patients with AHC present within the first 2 months of life; therefore, Dax1 appears to be essential for the normal development of the fetal adrenal gland. Our data show substantial enlargement of the fetal zone of the adrenal gland in a Dax1-deficient monkey; this phenotype closely resembles the adrenal gland phenotypes in DAX1-deficient human patients and mouse models (7) (8) (9) (10) (11) (12) .
The mechanisms underlying DAX1-deficiency-mediated AHC and HH in human are difficult to analyze. Adrenal insufficiency of AHC derives from impaired development of the adult zone of the adrenal cortex (8) , whereas HH-associated testis dysgenesis manifests with arrest of spermatogenesis or Sertoli cell only syndrome (7, (9) (10) (11) (12) . The Dax1 knockout monkey, which closely reflects phenotypic features of human AHC and HH, provided the opportunity to investigate potential disease mechanisms of AHC and HH. We observed elevated levels of β-catenin in testis tissue from the Dax1-deficient monkey, suggesting upregulation of Wnt signaling, which regulates angiogenesis, vascular remodeling and development (24, 25) . Consistent with these observations, VEGF, a downstream target of the Wnt signaling pathway, was upregulated in the testis, which may affect testis neovascularization (29) . Our results provide the first evidence that upregulation of the Wnt/β-catenin signaling pathway may be associated with DAX1-deficiency-mediated human AHC and HH.
In summary, we achieved efficient Dax1 targeting in the cynomolgus monkey by Cas9/sgRNA-mediated genome editing. Dax1 is required for fetal adrenal gland and testis development. The Dax1-deficient monkey embryo displayed abnormal fetal development of the adrenal gland, and testis dysgenesis with abnormal neovascularization, but intact Sertoli cell identity. All of these features recapitulate human AHC and HH caused by mutations in DAX1. Moreover, we observed upregulation of Wnt/β-catenin-VEGF in Dax1-deficient testis. Our study demonstrates that Dax1 gene targeting in monkeys models human AHC-HH and provides new insights into potential disease mechanisms. CRISPR/Cas9 genome editing in monkeys represents a suitable approach for the generation of valid animal models of human disease.
Materials and Methods
Animals
All cynomolgus monkeys (Macaca fascicularis) were housed at Kunming Biomed International (KBI). All animal work was approved by the Institutional Animal Care and Use Committee of Kunming Biomed International. The generation of gene-targeted cynomolgus monkeys by Cas9/RNA-mediated editing was previously described in detail (5).
T7EN1 cleavage assay and sequencing
Tissue samples were digested in lysis buffer as previously described (5) . Following DNA extraction, targeted sites were amplified by PrimerSTAR HS DNA polymerase (Takara, Japan) and purified with PCR cleanup kit (Axygen, USA). To detect T7EN1 cleavage products of Dax1 (localized on chromosome X) in fetal tissues, 50 ng of PCR fragment from wild-type control was mixed with 150 ng of PCR fragments from fetus injected with Cas9/sgRNAs. PCR products with mutations detected by T7EN1 cleavage assay were subcloned into T vector and sequenced. Primers for amplifying Dax1 targeted sites were previously described (5).
Hematoxylin and eosin staining
Testes and adrenal glands were fixed Bouin's solution and 4% paraformaldehyde, respectively, embedded in paraffin, and sectioned at 5 μm, deparaffinized and stained with hematoxylin and eosin (H&E). After dehydration through a series of graded ethanol baths and clearing in xylene, samples were mounted with neutral balsam and viewed with a bright-field microscopy (Axioskop 2 plus, ZEISS, Germany).
Immunohistochemistry and immunofluorescence
For immunohistochemistry, sections were deparaffinized in xylene and rehydrated using a series of graded ethanol baths. Endogenous peroxidase activity was blocked by incubation in 3% hydrogen peroxide for 15 min. After antigen retrieval in sodium citrate buffer, sections were blocked with a normal serum and incubated overnight at 4°C with primary antibodies. After three washes with phosphate-buffered saline (PBS), sections were incubated with a biotinylated secondary antibody and staining was visualized using a DAB substrate kit (Vector Laboratories, USA). For immunofluorescence, Alexa Fluor series secondary antibodies were applied, and images were captured on a Zeiss laser confocal microscopy (lsm710, Carl Zeiss, Germany). Antibodies information is listed in Supplementary Material, Table S3 .
Western blot analysis
Western blot was performed as described previously with minor modifications (34, 35) . Samples were separated by electrophoresis followed by transfer to polyvinylidene difluoride membranes (GE Healthcare, USA). The membranes were blocked and incubated overnight with primary antibodies (listed in Supplementary Material, Table S3 ). Membranes were washed and incubated at room temperature for 2 h with horseradish peroxidase (HRP)-conjugated secondary antibodies, followed by visualization of signal using the SuperSignal* West Femto Chemiluminescent Substrate Western blotting detection system (Thermo Scientific, USA).
Masson's trichrome stain
Sections were deparaffinized and re-hydrated into PBS, then mordanted with Bouin's solution overnight. After rinsed in water, sections were stained with Weigert's hematoxylin working solution, Biebrich scarlet-acid fuchsin solution, phosphomolybdic-phosphotungstic acid solution, aniline blue solution and 1% acetic acid solution, followed by mounting with Permount. Images were collected on a bright-field microscopy (Axioskop 2 plus, ZEISS, Germany).
Off-target assay
Off-target assay was performed as described before (5) . Briefly, all potential off-target sites with homology to the 23 bp sequence (sgRNA+PAM) were retrieved by a base-by-base scan of the whole rhesus genome (BGI CR_1.0/rheMac3), allowing for ungapped alignments with up to four mismatches in the sgRNA target sequence. In the output of the scan, potential offtarget sites with less than three mismatches in the seed sequence (one to eight bases) were selected to PCR amplification using genomic DNA as templates (Supplementary Material, Table S2 ). PCR products of putative off-target sites, amplified from liver, skin and spleen were subjected to T7EN1 cleavage assay. Samples with cleavage bands were further sequenced through TA cloning (Supplementary Material, Table S4 ). At least eight colonies for each sample were analyzed by DNA sequencing. The primer for amplifying the off-target sites were listed (Supplementary Material, Table S5 ).
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